Key result
Ambulatory levosimendan linked to ~21% higher stroke volume at 48 hours in advanced HF.
Why the study?
Although ambulatory infusions of levosimendan improve quality of life and reduce hospitalizations in advanced heart failure, their effects on echocardiographic markers of perfusion, congestion, and cardiovascular efficiency needed evaluation.
Does ambulatory infusion of levosimendan improve echocardiographic markers of perfusion and congestion in outpatients with advanced heart failure?
Comparison
Ambulatory levosimendan infusion evaluated before vs 48 hours after infusion
Design
Pilot study
Follow-up
48 hours after completion of ambulatory infusion
Loading...
May support short-term hemodynamic improvement in advanced HF outpatients; leaves open clinical outcomes and requires randomized confirmation.
Does ambulatory infusion of levosimendan improve echocardiographic markers of perfusion and congestion in outpatients with advanced heart failure?
Absolute Event Rate: 45.47% vs 37.47%
p-value: p=< 0.05
Ambulatory infusion of levosimendan in advanced heart failure patients significantly improves echocardiographic hemodynamic markers of perfusion and congestion at 48 hours.
A 2021 study studied Advanced heart failure (n=30). Levosimendan vs. Baseline (1 hour before infusion) was evaluated on Stroke volume (p=< 0.05). Ambulatory infusion of levosimendan in outpatients with advanced heart failure significantly increased stroke volume (45.47 vs 37.47 mL/beat; P<0.05) and cardiac output at 48 hours.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: